Ana M Rodriguez1, Mehmet R Asoglu1, Muhammet Erdal Sak2, Alai Tan3, Mostafa A Borahay1, Gokhan S Kilic4. 1. Department of Obstetrics & Gynecology, The University of Texas Medical Branch at Galveston, TX, USA. 2. Dicle University, Diyarbakir, Turkey. 3. Institute for Translational Sciences, The University of Texas Medical Branch at Galveston, TX, USA; Department of Preventive Medicine and Community Health, The University of Texas Medical Branch at Galveston, TX, USA. 4. Department of Obstetrics & Gynecology, The University of Texas Medical Branch at Galveston, TX, USA. Electronic address: gokilic@utmb.edu.
Abstract
OBJECTIVE: Our objective was to estimate the incidence of uterine leiomyosarcoma in patients with leiomyomas following laparoscopic supracervical hysterectomy and myomectomy procedures. STUDY DESIGN: For this study, we analyzed records of 13,964 women aged 25-64 years who underwent laparoscopic supracervical hysterectomies or myomectomies for leiomyomas from 2002 to 2011 using Clinformatics DataMart. Patient records were divided into two groups: history of laparoscopic supracervical hysterectomy and history of myomectomy. Subjects were tracked to identify diagnosis of leiomyosarcoma within 1 year of the procedure. We analyzed data from the 25-39, 40-49, and 50-64 age brackets. Evidence was obtained from a cohort study from national private insurance claims in the US. RESULTS: Our results showed the incidence of occult leiomyosarcoma developing within 1 year following supracervical hysterectomy using a laparoscopic-assisted approach are 9.8, 10.7, and 33.4 per 10,000 for the 25-39, 40-49, and 50-64 age brackets, respectively; the overall incidence rate is 13.1 per 10,000. The incidence rate of occult leiomyosarcoma developing within 1 year following myomectomy using a laparoscopic-assisted approach are 0.0, 33.8, and 90.1 per 10,000 for the 25-39, 40-49, and 50-64 age brackets, respectively; the overall incidence rate is 17.3 per 10,000. CONCLUSION: Our analysis shows the overall risk of being diagnosed with occult leiomyosarcoma is 12.9 per 10,000 in laparoscopic-assisted supracervical hysterectomy and myomectomy for patients younger than 49. There is no evidence of occult leiomyosarcoma 1 year after operation for patients younger than 40 who underwent laparoscopic myomectomy.
OBJECTIVE: Our objective was to estimate the incidence of uterine leiomyosarcoma in patients with leiomyomas following laparoscopic supracervical hysterectomy and myomectomy procedures. STUDY DESIGN: For this study, we analyzed records of 13,964 women aged 25-64 years who underwent laparoscopic supracervical hysterectomies or myomectomies for leiomyomas from 2002 to 2011 using Clinformatics DataMart. Patient records were divided into two groups: history of laparoscopic supracervical hysterectomy and history of myomectomy. Subjects were tracked to identify diagnosis of leiomyosarcoma within 1 year of the procedure. We analyzed data from the 25-39, 40-49, and 50-64 age brackets. Evidence was obtained from a cohort study from national private insurance claims in the US. RESULTS: Our results showed the incidence of occult leiomyosarcoma developing within 1 year following supracervical hysterectomy using a laparoscopic-assisted approach are 9.8, 10.7, and 33.4 per 10,000 for the 25-39, 40-49, and 50-64 age brackets, respectively; the overall incidence rate is 13.1 per 10,000. The incidence rate of occult leiomyosarcoma developing within 1 year following myomectomy using a laparoscopic-assisted approach are 0.0, 33.8, and 90.1 per 10,000 for the 25-39, 40-49, and 50-64 age brackets, respectively; the overall incidence rate is 17.3 per 10,000. CONCLUSION: Our analysis shows the overall risk of being diagnosed with occult leiomyosarcoma is 12.9 per 10,000 in laparoscopic-assisted supracervical hysterectomy and myomectomy for patients younger than 49. There is no evidence of occult leiomyosarcoma 1 year after operation for patients younger than 40 who underwent laparoscopic myomectomy.
Authors: Suzanne George; Constance Barysauskas; César Serrano; Titilope Oduyebo; Jose A Rauh-Hain; Marcela G Del Carmen; George D Demetri; Michael G Muto Journal: Cancer Date: 2014-06-12 Impact factor: 6.860
Authors: Jason D Wright; Ana I Tergas; William M Burke; Rosa R Cui; Cande V Ananth; Ling Chen; Dawn L Hershman Journal: JAMA Date: 2014-09-24 Impact factor: 56.272
Authors: Vrunda B Desai; Jason D Wright; Cary P Gross; Haiqun Lin; Francis P Boscoe; Lindsey M Hutchison; Peter E Schwartz; Xiao Xu Journal: Am J Obstet Gynecol Date: 2019-03-07 Impact factor: 8.661